PL399246A1 - Zastosowanie polimeru chitozanowego do leczenia i profilaktyki infekcji wywolanych przez koronawirusy - Google Patents

Zastosowanie polimeru chitozanowego do leczenia i profilaktyki infekcji wywolanych przez koronawirusy

Info

Publication number
PL399246A1
PL399246A1 PL399246A PL39924612A PL399246A1 PL 399246 A1 PL399246 A1 PL 399246A1 PL 399246 A PL399246 A PL 399246A PL 39924612 A PL39924612 A PL 39924612A PL 399246 A1 PL399246 A1 PL 399246A1
Authority
PL
Poland
Prior art keywords
coronaviruses
treatment
prophylaxis
infections caused
chitosan polymer
Prior art date
Application number
PL399246A
Other languages
English (en)
Other versions
PL225045B1 (pl
Inventor
Krzysztof Pyrc
Aleksandra Milewska
Maria Nowakowska
Krzysztof Szczubiałka
Kamil Kamiński
Original Assignee
Uniwersytet Jagiellonski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagiellonski filed Critical Uniwersytet Jagiellonski
Priority to PL399246A priority Critical patent/PL225045B1/pl
Priority to US14/401,921 priority patent/US20150164938A1/en
Priority to PCT/PL2013/000064 priority patent/WO2013172725A1/en
Priority to EP13729822.0A priority patent/EP2849763B1/en
Priority to CN201380025825.2A priority patent/CN104321063A/zh
Priority to KR1020147031937A priority patent/KR20150013526A/ko
Priority to JP2015512599A priority patent/JP6177893B2/ja
Priority to ES13729822.0T priority patent/ES2655674T3/es
Priority to CA2873171A priority patent/CA2873171A1/en
Priority to DK13729822.0T priority patent/DK2849763T3/en
Publication of PL399246A1 publication Critical patent/PL399246A1/pl
Publication of PL225045B1 publication Critical patent/PL225045B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem wynalazku jest zastosowanie polimeru chitozanowego o wzorze 1, w którym R oznacza H, COCH3 lub grupe -CH2CH(OH)CH2N+(CH3)3, do leczenia i profilaktyki infekcji wywolanych przez koronawirusy.
PL399246A 2012-05-18 2012-05-18 Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy PL225045B1 (pl)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL399246A PL225045B1 (pl) 2012-05-18 2012-05-18 Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy
US14/401,921 US20150164938A1 (en) 2012-05-18 2013-05-16 The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses
PCT/PL2013/000064 WO2013172725A1 (en) 2012-05-18 2013-05-16 The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses
EP13729822.0A EP2849763B1 (en) 2012-05-18 2013-05-16 The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses
CN201380025825.2A CN104321063A (zh) 2012-05-18 2013-05-16 壳聚糖聚合物用于治疗和预防冠状病毒引起的感染的用途
KR1020147031937A KR20150013526A (ko) 2012-05-18 2013-05-16 코로나바이러스에 의해서 야기된 감염의 치료 및 예방에서 키토산 중합체의 사용
JP2015512599A JP6177893B2 (ja) 2012-05-18 2013-05-16 コロナウイルスに起因する感染の治療及び予防におけるキトサンポリマーの使用
ES13729822.0T ES2655674T3 (es) 2012-05-18 2013-05-16 El uso de polímero de quitosano en el tratamiento y prevención de infecciones provocadas por coronavirus
CA2873171A CA2873171A1 (en) 2012-05-18 2013-05-16 The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses
DK13729822.0T DK2849763T3 (en) 2012-05-18 2013-05-16 Use of chitosan polymers to treat and prevent coronavirus infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL399246A PL225045B1 (pl) 2012-05-18 2012-05-18 Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy

Publications (2)

Publication Number Publication Date
PL399246A1 true PL399246A1 (pl) 2013-11-25
PL225045B1 PL225045B1 (pl) 2017-02-28

Family

ID=48652290

Family Applications (1)

Application Number Title Priority Date Filing Date
PL399246A PL225045B1 (pl) 2012-05-18 2012-05-18 Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy

Country Status (10)

Country Link
US (1) US20150164938A1 (pl)
EP (1) EP2849763B1 (pl)
JP (1) JP6177893B2 (pl)
KR (1) KR20150013526A (pl)
CN (1) CN104321063A (pl)
CA (1) CA2873171A1 (pl)
DK (1) DK2849763T3 (pl)
ES (1) ES2655674T3 (pl)
PL (1) PL225045B1 (pl)
WO (1) WO2013172725A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004081A2 (pt) 2018-09-04 2021-05-25 Ecole Polytechnique Federale De Lausanne (Epfl) nanopartículas virucidas, composição farmacêutica, composição virucida, método de desinfecção e/ou esterilização, dispositivo e uso das nanopartículas virucidas
WO2021209493A2 (en) 2020-04-15 2021-10-21 Solyplus Gmbh Means and methods of preventing and treating infections
JP2023522049A (ja) * 2020-04-15 2023-05-26 ソリープラス ゲーエムベーハー 感染を防止および処置する手段および方法
WO2022034494A1 (en) * 2020-08-11 2022-02-17 Council For Scientific And Industrial Research Anti-viral biodegradable modified polysaccharides
CN116367843A (zh) 2020-08-24 2023-06-30 纳诺莫里克斯有限公司 病毒抑制剂
WO2022135767A1 (en) 2020-12-22 2022-06-30 Solyplus Gmbh Means and methods of preventing, treating and detecting infections
CN114767707B (zh) * 2021-01-22 2024-05-03 艾美科健株式会社 包含低分子壳聚糖的用于预防或治疗冠状病毒感染疾病的组合物
DE102021000579B3 (de) 2021-01-28 2022-01-27 Apodis Gmbh Filterelement zur Filterung von Viren und/oder Bakterien aus einem Fluid, Filteranlage, Atemschutzmaske, Verfahren zur Herstellung des Filterelements und Verwendung einer Materialzusammensetzung
DE102021000578A1 (de) 2021-01-28 2022-07-28 Apodis Gmbh Filterelement zur Filterung von Viren und/oder Bakterien aus einem Fluid
WO2022246651A1 (zh) * 2021-05-25 2022-12-01 大连大学 低聚壳聚糖在制备抗新冠病毒药物中的应用
FR3133995A1 (fr) * 2022-03-31 2023-10-06 Health Plus Composition antivirale comprenant du chitosane et du xanthohumolone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229754B (it) * 1989-05-17 1991-09-10 Farmhispania Procedimento per la preparazione del chitosano e di suoi derivati contenenti gruppi di ammonio quaternario
AU644895B2 (en) 1990-08-23 1993-12-23 Dainippon Ink And Chemicals Inc. Antiviral agent
GB2262531B (en) 1991-12-17 1995-12-06 Erba Carlo Spa Antiviral sulphated polysaccharides
JPH07324014A (ja) * 1994-05-30 1995-12-12 Katakura Chitsukarin Kk カチオン性キトサン誘導体を含有する化粧料用防腐剤
IL129762A0 (en) 1996-11-14 2000-02-29 Biota Scient Management Novel macromolecules methods for their preparation pharmaceutical compositions thereof and their use as anti-influenza agents
US6306835B1 (en) * 1997-09-23 2001-10-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Biocidal chitosan derivatives
US20050209189A1 (en) 2001-03-06 2005-09-22 Roger Hershline Antiviral composition
CN100577179C (zh) * 2003-05-08 2010-01-06 天津帝士力投资控股集团有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
CN101057953A (zh) * 2006-04-21 2007-10-24 陈祖辉 对付病毒感染疾患的多靶协同防治制剂
EP2612872A3 (en) * 2006-06-02 2014-01-22 Synedgen, Inc. Chitosan-Derivative Compounds
WO2008105934A2 (en) * 2006-09-22 2008-09-04 Oregon Biomedical Engineering Institute, Inc. Inactivation of toxic agents and pathogens using chitosan
CN101554181A (zh) * 2008-04-07 2009-10-14 凯特森生物科技(北京)有限公司 甲壳素消毒液
WO2011114346A1 (en) * 2010-03-18 2011-09-22 Chetan Balar Chitin and related compounds for use in treating bacterial and viral infections
CN101792494A (zh) * 2010-03-26 2010-08-04 云南大学 一种硫酸化壳聚糖的新制备方法

Also Published As

Publication number Publication date
US20150164938A1 (en) 2015-06-18
PL225045B1 (pl) 2017-02-28
JP2015520755A (ja) 2015-07-23
EP2849763A1 (en) 2015-03-25
JP6177893B2 (ja) 2017-08-09
ES2655674T3 (es) 2018-02-21
WO2013172725A1 (en) 2013-11-21
CN104321063A (zh) 2015-01-28
DK2849763T3 (en) 2018-01-15
KR20150013526A (ko) 2015-02-05
CA2873171A1 (en) 2013-11-21
EP2849763B1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
PL399246A1 (pl) Zastosowanie polimeru chitozanowego do leczenia i profilaktyki infekcji wywolanych przez koronawirusy
WO2015003816A3 (en) Cystobactamides
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
IN2015DN01156A (pl)
MY173843A (en) Amidine substituted ?-lactam compounds, their preparation and use as antibacterial agents
BR112013016897A2 (pt) composição oftálmica aquosa
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
TN2014000416A1 (en) Nitrogenated heterocyclic compound
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
IN2013MU01749A (pl)
PH12014500887A1 (en) Aminoalkyl-substituted n-thienyl benzamide derivative
MX2015011193A (es) Compuestos antivirales.
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
MX2016009248A (es) Compuestos que contienen nitrogeno y su uso como agentes antibacterianos.
PH12015502241A1 (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel
BR112019027387A8 (pt) Composições imunogênicas
MX2015012472A (es) Derivados de manosa para el tratamiento de infecciones bacterianas.
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UA105260C2 (ru) Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
MX2015005753A (es) Agentes antimicrobianos.